-
Something wrong with this record ?
Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units
V. Vojtová, M. Kolár, K. Hricová, R. Uvízl, J. Neiser, L. Blahut, K. Urbánek,
Language English Country Italy
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21811750
Knihovny.cz E-resources
- MeSH
- Amikacin pharmacology MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Cefoperazone pharmacology MeSH
- Ceftazidime pharmacology MeSH
- Ciprofloxacin pharmacology MeSH
- Gentamicins pharmacology MeSH
- Intensive Care Units MeSH
- Penicillanic Acid analogs & derivatives pharmacology MeSH
- Microbial Sensitivity Tests MeSH
- Drug Resistance, Multiple, Bacterial MeSH
- Piperacillin pharmacology MeSH
- Pseudomonas aeruginosa drug effects MeSH
- Sulbactam pharmacology MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
Pseudomonas aeruginosa is one of the most frequent and dangerous pathogens involved in the etiology of severe nosocomial infections. A retrospective observational study was conducted at all intensive care units of the University Hospital in Olomouc, Czech Republic (155 ICU beds). Complete antibiotic utilization data of the ICUs in the period of 1999 to 2008 were processed according to ATC/DDD system and expressed in defined daily doses per 100 bed-days (DBD). Utilization of meropenem, imipenem, ciprofloxacin, ofloxacin, pefloxacin, gentamicin, amikacin, ceftazidime, cefoperazone, cefoperazone/sulbactam and piperacillin/tazobactam was measured. Pseudomonas aeruginosa strains were isolated from clinical material obtained from patients hospitalized in ICUs. During the ten-year period, utilization of the entire group of antibiotics monitored grew. It increased from 23.52 DBD in 1999 to 27.48 DBD in 2008 with a peak of 33.04 DBD in 2007. P. aeruginosa accounted for as much as 42% of pneumonias and 23% of surgical wound infections. Our results show that P. aeruginosa strains became gradually resistant to all antibiotics used in the treatment of the infections caused by them, with the exception of amikacin and piperacillin/tazobactam.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027459
- 003
- CZ-PrNML
- 005
- 20121210111327.0
- 007
- ta
- 008
- 120817e20110730it f 000 0#eng||
- 009
- AR
- 035 __
- $a (PubMed)21811750
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Vojtová, Vladimíra $u Department of Pharmacology, Faculty of Medicine, Palacky University and University Hospital Olomouc, Czech Republic.
- 245 10
- $a Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units / $c V. Vojtová, M. Kolár, K. Hricová, R. Uvízl, J. Neiser, L. Blahut, K. Urbánek,
- 520 9_
- $a Pseudomonas aeruginosa is one of the most frequent and dangerous pathogens involved in the etiology of severe nosocomial infections. A retrospective observational study was conducted at all intensive care units of the University Hospital in Olomouc, Czech Republic (155 ICU beds). Complete antibiotic utilization data of the ICUs in the period of 1999 to 2008 were processed according to ATC/DDD system and expressed in defined daily doses per 100 bed-days (DBD). Utilization of meropenem, imipenem, ciprofloxacin, ofloxacin, pefloxacin, gentamicin, amikacin, ceftazidime, cefoperazone, cefoperazone/sulbactam and piperacillin/tazobactam was measured. Pseudomonas aeruginosa strains were isolated from clinical material obtained from patients hospitalized in ICUs. During the ten-year period, utilization of the entire group of antibiotics monitored grew. It increased from 23.52 DBD in 1999 to 27.48 DBD in 2008 with a peak of 33.04 DBD in 2007. P. aeruginosa accounted for as much as 42% of pneumonias and 23% of surgical wound infections. Our results show that P. aeruginosa strains became gradually resistant to all antibiotics used in the treatment of the infections caused by them, with the exception of amikacin and piperacillin/tazobactam.
- 650 _2
- $a amikacin $x farmakologie $7 D000583
- 650 _2
- $a antibakteriální látky $x farmakologie $7 D000900
- 650 _2
- $a cefoperazon $x farmakologie $7 D002438
- 650 _2
- $a ceftazidim $x farmakologie $7 D002442
- 650 _2
- $a ciprofloxacin $x farmakologie $7 D002939
- 650 _2
- $a mnohočetná bakteriální léková rezistence $7 D024901
- 650 _2
- $a gentamiciny $x farmakologie $7 D005839
- 650 _2
- $a jednotky intenzivní péče $7 D007362
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a kyselina penicilanová $x analogy a deriváty $x farmakologie $7 D010397
- 650 _2
- $a piperacilin $x farmakologie $7 D010878
- 650 _2
- $a Pseudomonas aeruginosa $x účinky léků $7 D011550
- 650 _2
- $a sulbaktam $x farmakologie $7 D013407
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kolár, Milan
- 700 1_
- $a Hricová, Kristýna
- 700 1_
- $a Uvízl, Radek
- 700 1_
- $a Neiser, Jan
- 700 1_
- $a Blahut, Ladislav
- 700 1_
- $a Urbánek, Karel
- 773 0_
- $w MED00005605 $t The new microbiologica $x 1121-7138 $g Roč. 34, č. 3 (20110730), s. 291-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21811750 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121210111404 $b ABA008
- 999 __
- $a ok $b bmc $g 949501 $s 784805
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 34 $c 3 $d 291-8 $e 20110730 $i 1121-7138 $m The New microbiologica $n New Microbiol $x MED00005605
- LZP __
- $a Pubmed-20120817/11/03